Private Prescription: Skip NHS Queues, Choose Your Treatment
Which Is Better Wegovy or Mounjaro: Private vs NHS Route
The NHS route for weight management medications involves GP referral to specialist services, often with 6+ month waiting lists and strict eligibility criteria. Private prescription through EverydayMeds eliminates these barriers entirely. You can access both Wegovy and Mounjaro through our clinical assessment without any GP referral, receiving the same genuine medications prescribed through NHS services. This approach suits patients who meet clinical criteria but prefer not to wait for specialist appointments or navigate complex referral pathways.
Private prescription also offers treatment flexibility that NHS protocols may not accommodate. Our prescribers can discuss both Wegovy and Mounjaro options during your assessment, considering factors like your medical history, current medications, and lifestyle preferences. While NHS services typically follow standardised protocols, private care allows for more individualised treatment decisions, helping you understand which is better—Wegovy or Mounjaro—for your specific circumstances.
Wegovy vs Mounjaro Pricing: Private Prescription Costs
When considering which is better, Wegovy or Mounjaro, cost often influences decision-making for private patients. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient multi-dose options, like the Intro Duo (0.25mg & 0.5mg) for £169.99. New customers apply discount code FIRST40 at checkout, while returning patients use DOSE25.
Mounjaro pricing follows a different structure, reflecting its dual-action mechanism as a GIP and GLP-1 receptor agonist. Both medications require dose escalation over 16-20 weeks to reach maintenance levels, so initial treatment costs should factor in this titration period. Our clinical team can provide detailed cost projections during your assessment, helping you understand long-term financial commitments for either option when determining which is better—Wegovy or Mounjaro—for your budget and treatment goals.
Clinical Evidence: Which Is Better Wegovy or Mounjaro Studies
Clinical trials demonstrate both medications' efficacy, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Wegovy's STEP trials showed patients achieved approximately 15% average weight loss at 68 weeks alongside diet and exercise, while STEP 5 demonstrated sustained clinically studied weight loss at 2 years. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (Wilding et al., NEJM, 2021).
Mounjaro's SURMOUNT trials indicated potentially greater weight loss percentages, though comparing these results directly to Wegovy's STEP data may be misleading due to different methodologies and endpoints. Both medications demonstrated superior efficacy compared to placebo when combined with lifestyle interventions. Your prescriber can review this evidence in context of your health profile, helping determine which is better—Wegovy or Mounjaro—based on your individual risk factors and treatment objectives.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, glucagon-like peptide-1. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping you feel satisfied with smaller portions. GLP-1 also slows gastric emptying, meaning food stays in your stomach longer, promoting sustained fullness between meals. Additionally, Wegovy may reduce food cravings and the psychological drive to eat, particularly for high-calorie foods. Unlike appetite suppressants that simply block hunger signals, Wegovy works through natural hormonal pathways your body already uses for weight regulation. This prescription-only medicine must be used alongside a reduced-calorie diet and increased physical activity to achieve optimal results.
Private Prescription Process: From Assessment to Delivery
Our streamlined private prescription process eliminates traditional healthcare delays when you're deciding which is better, Wegovy or Mounjaro. The 3-minute online clinical assessment covers your medical history, current medications, weight management goals, and any contraindications to either treatment. Our prescribers review your submission within 3 working days (or 24 hours with express service), ensuring clinical safety and appropriateness for your chosen medication. Once approved, we dispatch your prescription-only medicine via next-day delivery using cold-chain transport to maintain medication integrity. This process bypasses GP appointments, specialist referrals, and lengthy NHS waiting lists while maintaining the same clinical safety standards. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine manufacturer medications with complete regulatory compliance throughout the private prescription pathway.
Storage and Practical Considerations
Storage requirements may influence your decision when comparing which is better, Wegovy or Mounjaro, particularly for frequent travellers or those with limited refrigeration access. Wegovy offers superior storage flexibility, maintaining stability for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use and come in pre-filled FlexTouch injection pens for convenient self-administration. The weekly injection schedule suits busy lifestyles better than daily medications, while the dose escalation protocol—starting at 0.25mg and increasing every 4 weeks to 2.4mg maintenance—allows your body to adjust gradually. Proper injection technique training is provided with your first prescription, ensuring confident self-administration throughout your treatment journey.
Mechanism Differences: Which Is Better Wegovy or Mounjaro Action
Understanding mechanism differences helps clarify which is better, Wegovy or Mounjaro, for your physiology and treatment goals. Wegovy targets GLP-1 receptors exclusively, focusing on appetite suppression and gastric emptying regulation through this single pathway. Mounjaro combines GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor activation, potentially offering broader metabolic effects through dual incretin action. This mechanistic difference may translate to varied treatment responses between individuals, though predicting who responds better to single versus dual incretin therapy remains clinically challenging.
Both medications work primarily through appetite reduction rather than metabolic acceleration, meaning sustainable results depend on continued treatment alongside lifestyle modifications. Neither represents a temporary "structured approach"—weight regain occurs when treatment stops, as demonstrated in STEP trial extensions where patients regained approximately two-thirds of lost weight within one year of discontinuation. Your prescriber can discuss these mechanistic differences in detail, helping you understand which is better, Wegovy or Mounjaro, based on your metabolic profile and long-term weight management strategy.
Start Your Private Treatment Today
Both Wegovy and Mounjaro are available from EverydayMeds, with our clinical team helping you determine which is better for your individual circumstances. New customers use discount code FIRST40 at checkout, while returning patients apply DOSE25 for optimal pricing on either medication. Our private prescription service provides immediate access to these advanced weight management treatments without NHS delays or complex referral requirements. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today. Remember that sustainable weight management requires long-term commitment to medication alongside dietary changes and increased physical activity—our prescribers support you throughout this journey with ongoing clinical guidance and prescription renewals as clinically appropriate.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
